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A B S T R A C T
The enzymatic synthesis of methotrexate (MTX) catalysed by α -chymotrypsin was studied for the first time. The
proteolytic enzyme displayed activity for the synthesis of MTX oligomers composed by 6 repeating units
(DPavg= 1.5). For longer oligomers, molecular dynamics simulations confirmed that as the oligomeric chain
grows its accommodation in the enzymes’ active site is hindered, which is evidenced by a decrease of the binding
energy associated. The full characterization of the oligomers produced was performed by nuclear magnetic
resonance (NMR, 1H and 13C), matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF), elec-
trospray ionization (ESI) and differential scanning calorimetry (DSC).
1. Introduction
The synthesis of polymeric drugs is an area with increasing interest
for the pharmaceutical industry that aims to improve their pharma-
ceutical performance mainly in applications requiring a drug-controlled
delivery. The controlled release, the improvement of safety and the
biodistribution profile, are some of the benefits associated to the ap-
plication of polymeric drugs [1]. The promising results obtained so far
in clinical trials using polymer-anticancer drug conjugates have been
raising the interest in the development of these type of drugs [2]. The
conjugation of poly(ethylene glycol) (PEG) with drugs is one of the
most studied strategies for the synthesis of polymer-drug conjugates,
being that some of the developed products have already reached the
market [3]. Recently, Suksiriworapong et al., synthetized a metho-
trexate-poly(glycerol adipate) conjugate, with improved toxicity for
Saos-2 cells than the unmodified methotrexate [4].
The polymer-drug conjugates or polymeric drugs are expected to be
easily hydrolysed in vivo, depending on the type of bond established
between the polymer and the drug or among the drug monomer units.
Prodrugs containing amide bonds are highly stable in vivo, being hy-
drolysed by carboxylesterases [5], peptidases or proteases [6]. Pro-
teases are enzymes commonly used for the hydrolysis of amide bonds
between two amino acids. Despite their hydrolytic activity, they are
also able to catalyse the inverse reaction, e.g. the formation of amide
bonds (peptides) [7]. The chemoenzymatic peptide synthesis is con-
sidered as a green chemistry practice to replace the typical methods,
liquid or solid phase peptide synthesis [8] taking advantage of the low
costs associated with the use of proteases as catalyst [9]. Enzymes like
papain, chymotrypsin, bromelain, trypsin and even lipase can be used
as catalysts of these type of reactions [7]. Qin et al. [9] studied the use
of papain for the biosynthesis of perfectly alternating oligopeptides.
They started by the synthesis of the dipeptide AG-OEt, followed by the
addition of papain and a short incubation period, isolating a peptide
with a maximum of 21 AG units. The authors mentioned that an ac-
curate choice of the ideal protease is crucial to afford oligomerization.
This selection is essential to avoid hydrolysis and/or transamidation
reactions during the process. The protease selection should rely on the
specificity of the enzyme, determined by their specific hydrolytic
properties between two amino acids. Following the same approach, the
same authors [10] studied the ability of α -chymotrypsin in the oligo-
merization between dipeptide KL-OEt. The selection of the protease
relied on its high specificity for the hydrolysis between -LK- residues.
After synthesis of the dipeptide KL-OEt, the α -chymotrypsin was
added, forming the expected oligomer. At a specific pH the enzyme
triggered the formation of an hydrogel due to the spontaneous self-as-
sembling of the KL chains into β-sheets. When papain was used for the
same purpose, no hydrogel was formed, and a random sequence of
oligopeptides was produced. The low selectivity of papain for the hy-
drolysis of -LK- bonds was responsible for the low reactional outcome.
Methotrexate is a commercially available drug for the treatment of
several cancers, auto-immune diseases, and rheumatoid arthritis [11].
However, this drug presents several limitations, such as poor solubility
in water, low resistance, high toxicity, and diverse side-effects asso-
ciated to its administration [12]. Due to the presence of both amine and
carboxylic acid groups in its composition, it represents an excellent
template for peptide bond formation. The conjugation of MTX with
polymers is a well explored strategy [4,13,14], however, as far as we
know, its self-polymerization has never been undertaken. The practical
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application of an oligomeric MTX is envisaged to decrease several ad-
verse side effects associated to its administration like its toxicity and
cell resistance [15].
In this work, we explored for the first time the ability of α -chy-
motrypsin to catalyse the oligomerization of methotrexate. The main
goal is to produce an oligomeric drug with improved properties in
comparison to the monomeric commercial alternative. Molecular dy-
namics simulations were performed to evaluate the affinity of metho-
trexate monomer, dimer and trimer, to the protease active site. The
resulting oligomers were fully characterized by NMR (1H and 13C),
MALDI-TOF, ESI and DSC.
2. Experimental
2.1. Materials
All compounds were purchase from Sigma-Aldrich or TCI chemicals,
and used without further purifications. α -chymotrypsin from bovine
pancreas type II, was purchase from Sigma-Aldrich, and used without
any further treatment.
2.2. Methods
2.2.1. General procedure for the synthesis of oligomeric methotrexate
To a solution of MTX di-sodium salt (10mg) in distillate water
(1 mL) was added NaOH until pH=9−10. α -chymotrypsin was then
added to the reaction (1mg) suspended in 200 μL of water. The solution
was placed in a water bath at 50 °C, 100 rpm for 7 days. After this time,
the enzyme is removed by centrifugation at 2500g using vivaspin
10 kDa (Sartorius).
2.2.2. Activity of α -chymotrypsin
The activity of α -chymotrypsin was measured using the universal
protease activity assay, with casein as substrate [16]. The activity is
calculated by the tyrosine units hydrolysed by the protease, detected at
660 nm after colorimetric reaction with Folin & Ciocalteu’s phenol re-
agent. Value of activity obtained: 0.61 U/mg. The values of the activity
are given as Units (U) of tyrosine per milligram of protease. The activity
of the α -chymotrypsin in the medium along time was evaluated by
incubating the enzyme under the same reactional conditions for the
synthesis of the oligomers, without addition of the methotrexate. At
different periods of time, an aliquot of the solution was removed, and
the activity was measured as mentioned.
2.2.3. NMR
1H and 13C NMR spectroscopy were performed using a Bruker
Avance III 400 (400MHz for 1H, 100MHz for 13C), using DMSO-d6 or
D2O (Cortecnet, France) as deuteride solvent and the peak solvent used
as internal reference. Heteronuclear single quantum coherence spec-
troscopy (HSQC) and heteronuclear multiple bond correlation (HMBC)
were also performed for an accurate signal assignment (Figure S4 and
S5). Signal multiplicity is given as: s (singlet), d (doublet), dd (doublet
of doublets), t (triplet) and m (multiplet).
NMR characterization of the isolated oligomeric methotrexate: 1H
NMR (D2O): δH 1.98–2.08 (m, 1 H), 2.13–2.21 (m, 1 H), 2.32 (t,
J=8.0 Hz, 2 H), 3.21 (s, 3 H), 4.31 (dd, J=4.4, 8.8 Hz, 1 H), 4.83 (s,
2 H), 6.92 (d, J=9.2 Hz, 2 H), 7.75 (d, J=8.8 Hz, 2 H) and 8.42 (s, 1 H)
ppm.
13C NMR (D2O): δC 28.5 (CH2), 34.3 (CH2), 38.5 (CH3), 55.4 (CH2),
55.9 (CH), 111.9 (CH), 120.7 (Cq), 128.4 (Cq), 129.0 (CH), 146.9 (CH),
147.7 (Cq), 151.9 (Cq), 155.6 (Cq), 163.7 (Cq), 169.7 (C=O), 172.7
(Cq), 179.3 (C=O) and 182.4 (C=O) ppm.
2.2.4. MALDI-TOF
MALDI-TOF mass spectra were acquired on a Bruker Autoflex Speed
instrument (Bruker Daltonics GmbH) equipped with a 1 kHz solid-state
smartbeam laser. The samples were prepared as reported [15] using
2,5-dihydroxybenzoic acid (DHB) as matrix, and analysed in the linear
negative mode. The number average molecular weight (Mn), weight
average molecular weight (Mw), polydispersity (PDI= Mw/Mn) and
average and maximum degree of polymerization (DPavg and DPmax)
were calculated using the data obtained from the MALDI spectra [17].
The conversion rate (p) was calculated based on Carothers equation,








Electrospray ionization was performed in a mass detector Thermo
Finnigan LxQ (Linear Ion Trap). The analysis was made using a mass
detector susceptible of analysis in full scan mode with negative ioni-
zation. The mass spectra range was between m/z 50 and 2000 and a
capillary voltage of 29 V was used. Samples were prepared using ul-
trapure water (Milli-Q) and methanol (HPLC grade, Fisher Chemical).
Prior to analysis, the sample was filtrated using a 0.2 μm filter
(Whatman).
2.2.6. DSC
All measurements were conducted on a power-compensated DSC
instrument (DSC 6000 Perkin Elmer) with a nitrogen flux of 20mL/min,
using stainless steel capsules in the temperature range of 20−300 °C
(heating rate: 10 °C/min, sample weight: 1-2 mg). The DSC device was
calibrated using indium and zinc, both of high purity. The samples were
freeze-dried for 24 h prior to the analyses and each sample was mea-
sured at least three times, in order to validate the results.
2.3. Molecular Dynamics simulations and docking
Bovine α -chymotrypsin, PDB ID: 1OXG, [18] with 2.2 Å resolution,
comprising residues 1−245, was chosen for the modelling experiments
in this work. The initial procedures used, as Molecular Dynamics si-
mulations, MTXs optimization and analyses, to settle the structures to
be used for docking, are described in the Supporting Information. One-
to-one binding model was considered to evaluate individually each
MTX molecule to the target α -chymotrypsin.
Docking experiments were performed with AutoDock 4.0 [19] and
prepared with the AutoDock Tools Software [19]. The middle structure
obtained for the native α -chymotrypsin, from the MD simulation at pH
9.5 and 323 K, were used as target macromolecule for the docking ex-
periments. A grid box was set according to the size of the oligomer,
ranging from 50×50×50–80× 80×100 in the case of trimer, with
a resolution of 0.375 Å. The grid box was centered in the active site -
catalytic triad - and grid potential maps were calculated using AutoGrid
4.0. We chose Lamarckian Genetic Algorithm (LGA) [19,20] as search
algorithm. Each docking consisted of 150 independent runs, with a
population of 150 individuals, a maximum number of 25× 105 energy
evaluations for MTX monomer and 25× 106 energy evaluations for
dimer and trimer (due the torsions of the oligomers), and a maximum
number of 27,000 generations. Additionally, the binding site preference
and interactions were identified through the AutoDock tools.
We analysed docking results looking at the binding energy and the
Ligand Efficiency (LE), which measures the binding energy per ligand
heavy-atom (kcal/HA) to understand how the increase in the oligomer
size contributes to the binding. Additional information about molecular
modelling studies is presented in the Supporting Information.
3. Results and discussion
3.1. α -chymotrypsin-catalysed synthesis of oligomeric MTX
The use of proteases as polymerization tools for the synthesis of
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peptides is being explored by several researchers [9,10]. Considering
the chemical structure of methotrexate, composed by two carboxylic
acids and two primary aromatic amines, we considered it as a pro-
mising template to evaluate the polymerase activity of α -chymotrypsin
(scheme 1 ). Moreover, the production of a polymeric drug would re-
present a promising strategy for the pharmaceutical industry regarding
its increased interest in the commercialization of these type of drugs
[21]. As an amide prodrug, the oligomeric MTX is expected to have
higher stability in the human body than the monomeric structure.
Moreover, the amide linkages of the oligomeric units, being more prone
to hydrolysis by enzymatic action, would improve drug metabolism and
decrease dosage administration [22,23]. The improved metabolism is
expected to result in a less toxic drug with lower side effects than the
commercial monomeric species [22,23].
Methotrexate di-sodium salt was used as starting material to ensure
water solubility and provide hydrophilic character to the produced
oligomers.
α -chymotrypsin was chosen for the MTX oligomerization based on
its well-known ability to polymerize peptides [10], showing its high
selectivity for the hydrolysis of aromatic amino-acids, such as tyrosine,
phenylalanine and tryptophan [24]. The reactional conditions, namely
temperature, pH and time, were optimized to reach the maximum oli-
gomerization degree (Table 1).
Most of the proteases have an optimum working pH between
7.0−9.0. Based on this feature, on the low basicity of the aromatic
amines and on the lack of reactivity of the pteridin ring, the reactions
were conducted under basic medium. Similar to what was previously
observed by Qin and co-workers [10] for the synthesis of –(KL)x- pep-
tides catalysed by α -chymotrypsin, we confirmed that no oligomers are
produced when the reactions were carried out at neutral pH (Table 1,
entries 1–3). For an efficient reaction synthesis, it is critical to perform
the reactions at alkaline pH, using NaOH as base (≈ 9.5, Table 1, en-
tries 4–8).
The best reactional outcomes were obtained herein when per-
forming the reactions at 50 °C, which is in accordance with the op-
timum temperature postulated by other authors for the same protein
[25].
During reaction, samples were withdrawn, and continuously mon-
itored by MALDI-TOF, until 2 weeks of reaction (Table 1, entries 4–8).
The best reactional outcome was achieved after 1 week of reaction with
the formation of oligomers composed by 6 monomeric units (DPmax).
Longer reactional times led to the recovery of similar-sized MTX oli-
gomers however in lower amount. The DP average calculated (1.5)
indicates that the most abundant specie in the reactional medium is the
methotrexate dimer, confirmed by MALDI-TOF and ESI (Table 2, Figure
S1). After one week of reaction, the enzyme converted 33 % of the
monomer molecules into oligomers, while the reaction carried out in
the absence of enzyme did not lead to the formation of any oligomeric
species (Table 1, entry 9 and Table 2).
In order to ensure an efficient oligomerization, it was imperative to
infer the maintenance of the basic pH during reaction. For this, the pH
was also continuously monitored and after 1 week of reaction, one
observed a pH decrease from 9.5 to 8, and to 7.5, after 2 weeks. We may
assume that some of the NaOH used to basify the medium was con-
sumed during the long reaction, therefore resulting in a pH decrease. As
the reaction occurs the NaOH is consumed by the low basic amines in
the pteridin ring, which were deprotonated, leading to a pH decrease.
The addition of NaOH was crucial to increase the amines reactivity and
proceed with the oligomerization.
It was noteworthy that the activity of α -chymotrypsin remained
almost unaltered during the first week of reaction (activity of 0.61 U/
mg), losing only 15 % of the initial activity after 2 weeks (activity of
0.52 U/mg). The high stability of the catalyst ensured the efficient
catalysis for longer periods of incubation.
3.2. Synthesis of dimeric MTX – proposed mechanism
Methotrexate, mainly composed by aromatic rings, is presented
herein as a suitable substrate for α -chymotrypsin. Based on the data
obtained, we have proposed a mechanism for the synthesis of a dimeric
unit of methotrexate catalysed by α -chymotrypsin (Fig. 1). The reac-
tion is predicted to start by the nucleophilic attack of the OH terminal
group of the serine, in the catalytic triad, to one of the carboxylic
groups of MTX (step 1), leading to the formation of the tetrahedral
Scheme 1. Reactional scheme for the oligomerization of methotrexate.
Table 1
Reactional conditions tested for the α-chymotrypsin-assisted synthesis of
methotrexate oligomers.
Entry Temperature pH Timea Methotrexate oligomers b,c
1 RT 7 1 week 1
2 50 °C 7 1 week 1
3 50 °C 7.8 1 week 1
4 50 °C 9.5 48 h 3
5 50 °C 9.5 72 h 3
6 50 °C 9.5 96 h 5
7 50 °C 9.5 1 week 6
8 50 °C 9.5 2 weeks 6
9 50 °C 9.5 1 week 1d
a Maximum time tested.
b Detected by MALDI-TOF, were 1 unit corresponds to the monomer.
c Maximum oligomeric units detected.
d Control reaction without enzyme.
Table 2
Conversion rate (%), average and maximum degree of polymerization (DPavg
and DPmax) analysed by MALDI-TOF and electrospray ionization (ESI), for the
oligomerization of methotrexate, with and without α-chymotrypsin.
With α-chymotrypsin Control (without enzyme)
Conversion ratea 33.4 % 0 %
DPavgb 1.5 1
DPmaxb 6 1
ESI 975.4 g/molc 453.28 g/mold
a Calculated by the Carothers equation.
b Calculated by MALDI-TOF.
c Most abundant specie, corresponding to the dimer. Mw dimer= 956.8,
where in ESI: 975=956 + Na+ - 4H+.
d Monomer Mw=454 g/mol or 498 g/mol (di-sodium form), where in ESI:
453=454−1H+.
J. Noro, et al. Process Biochemistry 98 (2020) 193–201
195
intermediate (step 2). The carboxylic group in the glutamic moiety,
which suffers the nucleophilic attack as depicted in Fig. 1, is reported as
the most reactive [15]. This carboxylic group is also less sterically
precluded, which is an important feature to afford oligomerization and
an effective catalysis by the protease. After release of a water molecule,
an MTX-enzyme complex is formed, through the formation of an ester
bond between MTX and the serine residue of the catalytic triad. This
reactive bond easily suffers a nucleophilic attack by one of the amines
in the pteridin ring of another MTX unit (step 3). The dimeric MTX is
then formed and released from the enzyme, where the catalytic triad of
α -chymotrypsin is restored (step 4).
Considering the data previously described, we may predict that the
reaction is not restricted to the synthesis of dimeric units, but it can go
further to longer species (DPmax= 6). The size of the oligomers is
however dependent on the affinity of MTX oligomers to the enzyme’
active site. Regarding the data obtained, we may infer that α -chymo-
trypsin is able to synthesize species until a maximum of 6 MTX units.
However, longer species are hampered to be synthesized due to ste-
reochemical constrains resulting from the molecular weight of MTX
(498 g/mol), which is comparably higher than the natural substrates of
this enzyme (amino acids, peptides).
For a better understanding of these findings, molecular dynamics
simulations were performed to evaluate the affinity of MTX and oli-
gomeric MTX to the active site of the enzyme and evaluate the role of
the substrate size on the enzyme activity.
3.3. Molecular dynamics simulations
Bovine α -chymotrypsin (PDB ID: 1OXG) [18] was evaluated under
different conditions of temperature and pH during Molecular Dynamics
(MD) simulations. Firstly, the enzyme was evaluated at 310 K and
physiological pH, then at 323 K and pH 9.5; this second simulation was
performed to mimic the experimental conditions used. RMSD results
(Figure S2), indicate that the experiment conditions established are the
ideal to study the enzyme behaviour, since the enzyme demonstrates to
be more stable at the higher temperature and pH. Figure S3 shows the α
-chymotrypsin crystallographic structure (A) highlighting the active
site, where the catalytic triad composed by HIS 57, ASP 102 and SER
195 takes place, and the electrostatic distribution for this enzyme (B).
MTX and MTX oligomeric structures were predicted at PM6 level
[26], a semi-empirical method that performs geometry optimization
and charge distribution, making the structures suitable to be used for
molecular docking. In the case of MTX, the neutral and negative forms
(at pH 9.5) were evaluated. The structures presented in Fig. 2 were used
in Molecular Docking experiments.
Overall, monomer (MTX), dimer and trimer have an increasing
flexibility due to the increasing number of torsions. Dimer and trimer
(Fig. 2, C–D) optimized with PM6, can undergo more "bent" con-
formations when submitted to docking, due to the higher number of
torsions.
Docking experiments were conducted in order to understand the
interactions between MTX and α -chymotrypsin, and the role of this
enzyme in the synthesis process. We select an area that enwrap the
active site with enough space to comprise the MTX units (monomer,
dimer or trimer) to dock. Fig. 3 shows the correlation between the MTX
and enzyme, and the binding energy involved for each case studied.
MTX complexed to α -chymotrypsin, present a binding energy of
-6.94 kcal/mol (-29.04 kJ/mol) and a Ligand Efficiency (LE) of
-0.19 kcal/HA (-0.79 kJ/HA). The monomer has hydrogen bonds with
ALA56, GLY59, SER96, TYR94 and THR104, and van der Waals inter-
actions are found with HIS57 and ASP102. For dimeric MTX, GLY59
and TYR94 are also involved in hydrogen bonds, as well as LYS90 and
Fig. 1. Proposed mechanism for the synthesis of a dimeric unit of methotrexate catalysed by α-chymotrypsin.
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ASN95. The binding energy is -6.35 kcal/mol (-26.61 kJ/mol) in this
case, and a LE of -0.1 kcal/HA (-0.42 kJ/HA). HIS57 is still a close
contact for MTX dimer.
The trimer binds to the enzyme with -5.45 kcal/mol (-22.80 kJ/mol)
and LE of -0.06 kcal/HA (-0.25 kJ/mol). Similarly, HIS57 and ASP102
interact with the trimer. In addition, five hydrogen bonds are found,
two with SER96 and the others with LEU97, ASN91, and THR104. In all
the three cases, electrostatics interactions are also present, between the
carboxylic acids of MTX and the positive region observed in Figure S3
(B).
Farhadian and co-workers recently reported docking experiments
with α-chymotrypsin [27,28]. However, the complexes were not
formed in the active site, where the catalytic triad take place. Some
other works addressing the docking near the catalytic site do not reveal
the complex binding energy for the association of a molecule to the
protein [29,30]. Other larger molecules have been described to
efficiently bind to α-chymotrypsin, however these molecules are used
as inhibitors, and therefore cannot be compared to our work [30]. The
lack of similar docking approaches makes it difficult to compare our
binding preferences and energies with other studies. Moreover, the
conversion of the binding energy to association constants is also hard to
obtain. In docking experiments, the protein is static, the whole long-
range electrostatics is not considered, and no water molecule is present.
Therefore, the use of the equation ΔG = -RT ln Ka, would lead to a
rough approximation.
All these interactions demonstrate the ability of MTX to bind to the
protease active site, leading to the formation of oligomeric MTX. Even
though being possible more interactions of longer MTX forms with the
protease, the binding energy decreases discretely as well as the LE per
heavy-atom. One may infer that this is due to the energy penalties re-
sulting from the increased number of torsions and desolvation for the
bulky forms of MTX (dimer and trimer), since they can undergo to more
Fig. 2. (A) skeletal and 3-D methotrexate (MTX) structures at pH 7.0 and (B) the deprotonated forms at pH 9.5. (C) skeletal and 3-D structures of MTX dimer, at pH
9.5 and (D) shows the trimer 3-D representation. The colour scheme use green for carbon, blue for nitrogen, red for oxygen and white for hydrogen.
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conformations, as previously observed during docking experiments. The
results indicate a decrease of the binding energy as the oligomer chain
grows, justifying that only a maximum of 6 units of MTX could be
biosynthesized by α -chymotrypsin.
3.4. MTX oligomers characterization
3.4.1. NMR spectroscopy
By 1H NMR spectroscopy, it is possible to detect differences between
MTX oligomers and the starting material (monomer). In the spectra of
free MTX, the signals appeared at δH 8.56, 8.13 (NH), 7.62, 7.38 (NH),
6.81, 6.58 ppm (NH2), in the aromatic region (Fig. 4A). The spectra of
oligomeric MTX (Fig. 4B) show significant chemical shifts in the pter-
idine ring, δH 8.15 (b), 8.14 (NH), 7.62, 6.78 ppm. The pattern of the
signals remained the same as in the monomer MTX, confirming that the
amide bond (near proton g) is not hydrolysed by the protease during the
oligomerization reaction. Bidimensional spectra (HSQC and HMBC)
were also performed to allow an accurate signal assignment (Figure S4
and S5).
3.4.2. MALDI-TOF and ESI
MALDI-TOF spectra displays the pattern of MTX oligomers catalysed
by α-chymotrypsin (Fig. 5B) and of the control reaction without en-
zyme, showing the peak of the monomer below m/z 500 (Fig. 5A). By
ESI the ion peak corresponding to the monomer is observed at m/z 453
(Figure S1 A) and no fragmentation is detected. The most abundant
specie detected by ESI on the samples catalysed by α-chymotrypsin is a
dimer (Figure S1 B).
Regarding the oligomer spectrum (Fig. 5B), (MTX)1 is observed at
475 Da [498-Na+], whereas a repetitive pattern of m/z of ≈521 Da is
detected. This behaviour is observed until a maximum m/z of
3112.61 Da, attributed to the longest oligomer obtained composed by 6
Fig. 3. Docking poses showing the interaction of α-chymotrypsin with the different methotrexate species, and the respective binding energies obtained using
AutoDock 4.0: A) α-chymotrypsin with methotrexate; B) α-chymotrypsin with dimeric methotrexate and C) α-chymotrypsin with trimeric methotrexate. Surface/
cavities representation are in the right panel. Enzyme is represented in light grey, hydrogen bonds in yellow dashes and methotrexates following the scheme previous
described in Fig. 2. Values in SI units: A) -29.04 kJ/mol; B) -26.61 kJ/mol and C) -22.80 kJ/mol.
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MTX units. The repeating unit between species (≈521 Da) corresponds
to the tri-sodium methotrexate, most probably resulting from the pre-
sence of the NaOH on the reactional medium, which may be linked to
more than one amine in the pteridin ring. Additional sodium was also
found on the recorded ESI spectra of the oligomer.
In Table 3 are summarized the results obtained expressed in terms of
number average molecular weight (Mn), weight average molecular
weight (Mw) and PDI (Mw/Mn). The oligomers produced by the pro-
tease showed a Mn value of 724.8 g/mol and a Mw of 1225.7 g/mol.
The polydispersity index obtained was 1.69, showing some sample
heterogeneity.
3.4.3. DSC
The DSC analysis highlights differentiated thermal behaviour de-
pending on the size of the MTX oligomers (Fig. 6). The monomeric MTX
show a melting point at 139 °C (black line) and no other thermal events
are observed at higher temperatures. As the chain length grows higher
melting points are expected. The oligomers synthetized by the protease
(red line), showed a melting point at 184 °C.
4. Conclusions
In this work the synthesis of MTX oligomers assisted by α-chymo-
trypsin was undertaken for the first time. The oligomeric species
Fig. 4. 1H NMR (DMSO-d6) spectra of A) methotrexate and B) methotrexate oligomers synthesized by α-chymotrypsin.
Fig. 5. MALDI-TOF spectra of A) control reaction carried without enzyme, and B) oligomeric methotrexate synthetized by α-chymotrypsin.
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obtained were predominantly small (dimers) due to the size of the
monomer (MTX, Mw=498 g/mol), which imparted stereochemical
impediments to the active site. Operational conditions like temperature
(50 °C) and pH (9–10) were found critical for the efficient oligomer-
ization. Molecular dynamics simulations confirmed that as the oligo-
meric chain grows, its accommodation in the active site is hindered,
which is evidenced by a decrease of the binding energy associated
(-6.94 kcal/mol for the monomer and -5.45 kcal/mol for the trimer).
The data also revealed that α-chymotrypsin is able to synthesize oli-
gomeric species with 6 units, however in a lower extent (33 %).
α-chymotrypsin is presented herein as a versatile catalyst for oli-
gomer synthesis, even for substrates that are not naturally catalysed by
it, like methotrexate. Moreover, the oligomerization of this drug would
represent an alternative route for the treatment of many diseases, by
reducing some side effects associated to the monomer administration.
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